Beckley Psytech

This week is #BrainAwarenessWeek, a global initiative to highlight the latest advances in neuroscience. So what better time to share an update on the first-of-its-kind brain imaging study taking place at Imperial College London with our 5-MeO-DMT benzoate compound, BPL-003? This is the first lab-based, placebo-controlled study investigating the effects of 5-MeO-DMT on the human brain using high-density EEG and the research may shed new light on how psychedelics like 5-MeO-DMT impact brain activity, particularly in relation to perceived ego dissolution. To mark the occasion, we caught up with Dr. Chris Timmermann, Head of the DMT Research Group at Imperial, and Tommaso Barba, a PhD researcher coordinating the study, for a quick Q&A on the latest insights. Read more below.

We’re excited to announce that we have completed enrolment in the core stage of our global Phase IIb study evaluating BPL-003, our proprietary intranasal formulation of 5-MeO-DMT, for Treatment Resistant Depression. The study is thought to be the largest ever controlled clinical study to investigate 5-MeO-DMT - with 196 patients enroled across 38 sites in 6 countries - as well as the first and only blinded Phase II clinical trial of 5-MeO-DMT in the United States. Topline results are expected in mid-2025. Thank you to all our trial participants and research partners for making this study possible. We look forward to sharing the data soon! More info: https://lnkd.in/eQYBZCVX

🌍🔬 Today is International Day of Women and Girls in Science - a day to celebrate the achievements of women in STEM and push for greater inclusivity, equality, and representation. At Beckley Psytech, we’re proud to highlight the voices of the incredible women driving innovation in our team. We spoke with four of them (Anna Ermakova, Berrak (Kocaoglu) Selek, Chandni Hindocha, Ph.D. and Karen Williams) about their experiences working in the space and their hopes for the future. Together, we can challenge stereotypes, champion role models, and support the next generation of women in STEM. #IDWGS #WomenInSTEM #DiversityInScience 

We are thrilled to share positive topline data from our Phase IIa study of BPL-003 for Alcohol Use Disorder today. The study (which took place at King's College London and Clerkenwell Health in the UK) demonstrated that a single dose of BPL-003:  ✅ Was well-tolerated ✅ Produced a meaningful and sustained reduction in alcohol use, with complete abstinence maintained in 50% of patients for the full 3-month evaluation period. ✅ Delivered a significant and durable decrease in Heavy Drinking Days (HDDs) with the mean percentage of HDDs dropping from 56% in the pre-dose period to 13% at the end of the study. With around 400 million people across the globe living with AUD, there is an urgent need for more effective treatments. Learn more about our study and findings here: https://lnkd.in/eynDZ--q

Initial findings from our proof-of-concept Phase IIa study of ELE-101 for Major Depressive Disorder have been shared today. Commenting on the news, Dr Rob Conley, Beckley Psytech’s Chief Scientific and Medical Officer, said: “These positive initial findings indicate that our innovative intravenous formulation has the potential to provide an effective and rapid-acting treatment option for those suffering from depression, with a good safety and tolerability profile and lasting effects from a single dose. Whilst this was a small, proof-of-concept study, we are greatly encouraged by the results and we are looking forward to planning larger studies of ELE-101 in the coming months.” Learn more about the study, and our future plans, on our website: https://lnkd.in/ewiHM25H

🧠 How could next-generations psychedelics transform mental health care? In this fascinating episode of The Healthtech Podcast with Dr. James Somauroo, our CEO, Cosmo Feilding Mellen, explores the science, safety, and societal impact behind psychedelic-based therapies. Whether you're curious about the future of mental health or want to understand the clinical landscape, tune in to learn more about the work we're doing to develop effective, rapid-acting and accessible medicines for people in need. 🎧 Listen here: https://lnkd.in/etJ4ayjk

ICYMI: Our CEO, Cosmo Feilding Mellen, caught up with TIME to discuss how our novel short-acting, psychedelic-based candidates could revolutionise the treatment of mental health conditions. Learn more here: https://lnkd.in/grJTzNWg

"I believe, in a decade from now, multiple psychedelics will be prescribed as legal medicines for a whole range of psychiatric conditions". In this fascinating interview with Evan Baehr, Beckley Psytech's CEO, Cosmo Feilding Mellen, shares his unique journey from growing up at the heart of the psychedelic revolution to leading the charge in plant-based medicine for conditions like depression and substance abuse. If you're curious about the future of mental health, tune in to learn more. https://lnkd.in/etNEk2Vr

How do you progress a psychedelic-based treatment through development and onto patients in need? That's what our Founder and CEO, Cosmo Feilding Mellen, discussed with Brandon Li on the 'Power to the Patients' podcast, where he covered everything from why we're looking at compounds that elicit a short treatment duration to ethics in psychedelic medicine development. Full episode in the comments.

Check out our CEO, Cosmo Feilding Mellen on the ‘Power to the Patients’ podcast where he talks about: 🌱 The founding story of Beckley Psytech 🚀 Our mission to develop effective and accessible medicines for mental health conditions and why we're focusing on next-generation compounds. 🧠 Our recent study results that show a single dose of our lead compound, BPL-003, can produce rapid and lasting effects for people with depression. Click through to listen here: https://lnkd.in/ecpWxput